» Articles » PMID: 37959392

A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Nov 14
PMID 37959392
Authors
Affiliations
Soon will be listed here.
Abstract

A PRoliferation-Inducing Ligand (APRIL), the thirteenth member of the tumor necrosis factor superfamily, plays a key role in the regulation of activated B cells, the survival of long-lived plasma cells, and immunoglobulin (Ig) isotype class switching. Several lines of evidence have implicated APRIL in the pathogenesis of IgA nephropathy (IgAN). Globally, IgAN is the most common primary glomerulonephritis, and it can progress to end-stage kidney disease; yet, disease-modifying treatments for this condition have historically been lacking. The preliminary data in ongoing clinical trials indicate that APRIL inhibition can reduce proteinuria and slow the rate of kidney disease progression by acting at an upstream level in IgAN pathogenesis. In this review, we examine what is known about the physiologic roles of APRIL and evaluate the experimental and epidemiological evidence describing how these normal biologic processes are thought to be subverted in IgAN. The weight of the preclinical, clinical, and genetic data supporting a key role for APRIL in IgAN has galvanized pharmacologic research, and several anti-APRIL drug candidates have now entered clinical development for IgAN. Herein, we present an overview of the clinical results to date. Finally, we explore where more research and evidence are needed to transform potential therapies into clinical benefits for patients with IgAN.

Citing Articles

Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.

Dong L, Yang D, Qin A, Wang S, Tang Y, Tan J Ren Fail. 2025; 47(1):2449580.

PMID: 39780498 PMC: 11721934. DOI: 10.1080/0886022X.2025.2449580.


Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine.

Kanbay M, Ozbek L, Guldan M, Copur S, Barratt J J Nephrol. 2024; .

PMID: 39565563 DOI: 10.1007/s40620-024-02149-6.


Drugs in Development to Treat IgA Nephropathy.

Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F Drugs. 2024; 84(5):503-525.

PMID: 38777962 DOI: 10.1007/s40265-024-02036-1.

References
1.
Schrezenmeier E, Jayne D, Dorner T . Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. J Am Soc Nephrol. 2018; 29(3):741-758. PMC: 5827591. DOI: 10.1681/ASN.2017040367. View

2.
Kim J, Kim S, Cheong J, Kim Y, Hwang D, Yoon S . Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Korean J Hematol. 2011; 46(3):175-9. PMC: 3208200. DOI: 10.5045/kjh.2011.46.3.175. View

3.
Yeo S, Cheung C, Barratt J . New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2017; 33(5):763-777. PMC: 5861174. DOI: 10.1007/s00467-017-3699-z. View

4.
Dillon S, Gross J, Ansell S, Novak A . An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):235-46. DOI: 10.1038/nrd1982. View

5.
Lopez-Fraga M, Fernandez R, Albar J, Hahne M . Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001; 2(10):945-51. PMC: 1084076. DOI: 10.1093/embo-reports/kve198. View